Strategic Collaborations

Identifying partners at points of value inflection.

Balanced Partnering Approach

We look to be a transparent and trustworthy partner, while taking a strategic and focused approach to product development. As Sangamo’s therapeutic programs progress, we balance external collaborations with forward integration on select assets that align with our strategic vision of one-time treatment therapeutics and our business model.

Balanced Partnering Approach

Therapeutic Collaborations

Our business strategy is to do what we do best — develop gene therapy, genome editing, cell therapy and gene regulation products through research, preclinical and early stage clinical testing. We then look for partners with key value drivers to help us fully realize the value of certain programs through late stage development and commercialization.

Bioverativ Inc.

Bioverativ Inc.

We have a collaboration with Bioverativ Inc., the blood disorder focused spin-off of Biogen, to research, develop, and commercialize therapeutics for hemoglobinopathies, based on our ZFN-mediated genome editing cell therapy platform, specifically targeting rare blood diseases beta thalassemia and sickle cell disease.

Shire International GmbH

Shire International GmbH

We have a collaborative partnership with Shire plc to develop and commercialize therapeutics for Huntington's disease utilizing our ZFP Transcription Factor (ZFP TF) gene regulation platform.

Multi-Platform Approach to Gene-Based Therapeutics

Learn more about our four technology platforms and therapeutic focus areas.

Interested in Partnering with Us?

Please email Curt Herberts, Senior Vice President and CBO at cherberts@sangamo.com.